Advances in clinical chemistry. Volume sixty five /

• Άλλοι συγγραφείς: Makowski, Gregory (Επιμελητής έκδοσης), Menéndez, Francisco V. Álvarez (Συντελεστής)
• Μορφή: Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: San Diego, California : Academic Press, 2014.
• Σειρά: Advances in Clinical Chemistry ; v. 65.
• Θέματα: Clinical chemistry.; Biochemistry.; Electronic books.

Volume 65 in the internationally acclaimed Advances in Clinical Chemistry contains chapters authored by world renowned clinical laboratory scientists, physicians and research scientists. The serial provides the latest and most up-to-date technologies related to the field of Clinical Chemistry and is...

Πίνακας περιεχομένων:

• Front Cover; Advances in Clinical Chemistry; Copyright; Contents; Contributors; Preface; Chapter One: HDL Metabolism and Atheroprotection: Predictive Value of Lipid Transfers; 1. Introduction; 2. HDL Composition; 3. HDL Subclasses; 4. HDL Metabolism and Reverse Cholesterol Transport; 5. Other HDL Functions; 6. Proatherogenic HDL; 7. Cholesterol Ester Transfer Protein; 7.1. CETP inhibitors; 8. Phospholipid Transfer Protein; 9. CETP and PLTP in CVD; 10. Simultaneous Transfer of Lipids to HDL; 11. Conclusion; Acknowledgments; References; Chapter Two: Diagnosis of Infection in Critical Care.
• 1. Background2. Immunologic Basis of Sepsis; 2.1. Innate immunity and inflammation in sepsis; 2.2. Procoagulant-anticoagulant equilibrium; 3. New Tools for Bacterial Identification; 4. Useful Markers of Infectious Complications According to the Affected Organ and Patient Status; 4.1. Central nervous system complications in septic patients; 4.2. Renal failure during sepsis; 4.3. Infection severity after trauma or surgery; 4.4. Liver transplantation and infections; 4.5. Infections in critically ill pediatric patients; 4.6. Early recognition of severe sepsis in community-acquired pneumonia.
• 4.7. Cell-free DNA as a potential marker of infection5. Conclusions; References; Chapter Three: Metabolomics in Nephrotoxicity; 1. Introduction; 2. Nephrotoxicity or Renal Toxicity; 3. Metabolomics in Biomarker Discovery; 4. Metabolomics Application in Animal Model-Based Nephrotoxicity; 4.1. Antibiotics; 4.2. Immunosuppressive drugs; 4.3. Chemotherapeutics; 4.4. Natural medicines; 4.5. Environmental pollutants; 4.6. Melamine; 4.7. Other nephrotoxicity; 5. Metabolomics in Clinical Nephrotoxicity; 5.1. Immunosuppressive drugs-induced nephrotoxicity; 5.2. Melamine; 5.3. Cancer; 5.4. ARI.
• 6. Conclusion and Future PerspectivesAcknowledgments; References; Chapter Four: Metabolic Syndrome in Pediatrics; 1. Introduction; 2. Clinical Features of Children with Metabolic Syndrome; 2.1. Clinical measures of adiposity: BMI or waist circumference?; 2.2. Family history and acanthosis nigricans; 3. Metabolic Characteristics of Children and Adolescents with Metabolic Syndrome; 3.1. Hypertension; 3.2. Dyslipidemia; 3.3. Puberty as cause of transient insulin resistance; 3.4. Subtle inflammation in obese insulin-resistant youth; 4. Prediabetes and Type 2 Diabetes in Youth.
• 5. Nonalcoholic Fatty Liver Disease in Youth5.1. Association between fatty liver and metabolic syndrome; 5.2. Pathogenesis and progression of NAFLD; 5.3. Common gene variants associated with hepatic steatosis and liver damage; 6. Association Between ``Lipid partitioning ́ ́ and Metabolic Syndrome; 7. Is There a Healthy Metabolic Phenotype in Obesity?; 8. Role of Subcutaneous Fat in the Pathogenesis of Metabolic Syndrome; 9. Novel Biomarkers of Metabolic Syndrome; 9.1. The fibroblast growth factor 21; 9.2. Leptin; 9.3. Adiponectin; 9.4. Chemerin; 9.5. Omentin; 9.6. Resistin; 9.7. Visfatin.